{"id":185808,"date":"2026-03-09T13:48:22","date_gmt":"2026-03-09T13:48:22","guid":{"rendered":"https:\/\/www.europesays.com\/se\/185808\/"},"modified":"2026-03-09T13:48:22","modified_gmt":"2026-03-09T13:48:22","slug":"omtag-i-tyskland-och-ny-indikation-oncopeptides-vd-berattar-mer","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/185808\/","title":{"rendered":"Omtag i Tyskland och ny indikation \u2013 Oncopeptides vd ber\u00e4ttar mer"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\"><strong>Just nu p\u00e5g\u00e5r Oncopeptides f\u00f6retr\u00e4desemission, som l\u00f6per fram till 16 mars. Bolaget siktar d\u00e4r p\u00e5 att ta in upp till 200 miljoner kronor f\u00f6r att forts\u00e4tta driva f\u00f6rs\u00e4ljningen av Pepaxti, samtidigt som man ger sig in i en ny indikation med sin teknik: glioblastom. BioStock bj\u00f6d in vd Sofia Heigis till en pratstund f\u00f6r att f\u00e5 veta mer om var bolaget st\u00e5r i dag och vad hon ser framf\u00f6r sig fram\u00f6ver. <\/strong><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Se hela intervjun h\u00e4r nedan.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">The post <a class=\"text-primary-90 hover:text-primary-110 underline hover:no-underline\" rel=\"noopener noreferrer nofollow\" target=\"_blank\" href=\"https:\/\/biostock.se\/2026\/03\/omtag-i-tyskland-och-ny-indikation-oncopeptides-vd-berattar-mer\/\">Omtag i Tyskland och ny indikation \u2013 Oncopeptides vd ber\u00e4ttar mer<\/a> appeared first on <a class=\"text-primary-90 hover:text-primary-110 underline hover:no-underline\" rel=\"noopener noreferrer nofollow\" target=\"_blank\" href=\"https:\/\/biostock.se\">Biostock<\/a>.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">BioStock \u00e4r en nyhetstj\u00e4nst och tillhandah\u00e5ller inte investeringsr\u00e5dgivning, f\u00f6rmedlar inga investeringsorder och tar inget ansvar f\u00f6r agerande och\/eller eventuell f\u00f6rlust eller skada av n\u00e5got slag som grundar sig p\u00e5 anv\u00e4ndandet av inneh\u00e5ll som publicerats p\u00e5 BioStock.se. Varje investeringsbeslut fattas ist\u00e4llet sj\u00e4lvst\u00e4ndigt av den enskilde investeraren. Inneh\u00e5llet i BioStocks nyheter och analyser \u00e4r oberoende men d\u00e5 BioStocks verksamhet delvis \u00e4r finansierad av bolag i branschen kan BioStocks webbplats inneh\u00e5lla nyheter om bolag som BioStock erh\u00e5llit finansiering fr\u00e5n.\u00a0Detta material har uppr\u00e4ttats i marknadsf\u00f6ringssyfte och \u00e4r inte och ska inte anses utg\u00f6ra ett prospekt enligt g\u00e4llande lagar och regler. De fullst\u00e4ndiga villkoren f\u00f6r f\u00f6retr\u00e4desemissionen och mer information om bolaget har redovisats i ett prospekt som offentliggjorts och publicerats p\u00e5 n\u00e4mnda bolags hemsida.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\"><a class=\"text-primary-90 hover:text-primary-110 underline hover:no-underline\" rel=\"noopener noreferrer nofollow\" target=\"_blank\" href=\"https:\/\/biostock.se\/2026\/03\/omtag-i-tyskland-och-ny-indikation-oncopeptides-vd-berattar-mer\/\">L\u00e4s mer p\u00e5 BioStock<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Just nu p\u00e5g\u00e5r Oncopeptides f\u00f6retr\u00e4desemission, som l\u00f6per fram till 16 mars. Bolaget siktar d\u00e4r p\u00e5 att ta in&hellip;\n","protected":false},"author":2,"featured_media":164641,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[5],"tags":[22,23,26,27,17,21,24,25,28,29,15,16,6576,18,34,31,33,32,30,19,20],"class_list":["post-185808","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rubriker","tag-breaking-news","tag-breakingnews","tag-featured-news","tag-featurednews","tag-headlines","tag-huvudnyheter","tag-latest-news","tag-latestnews","tag-main-news","tag-mainnews","tag-news","tag-nyheter","tag-oncopeptides","tag-rubriker","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-top-stories","tag-topstories"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116199535671909013","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/185808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=185808"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/185808\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/164641"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=185808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=185808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=185808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}